Stryker Corporation

New York Stock Exchange
Back to all articles
Somewhat Bullish +50

J.P. Morgan Keeps Their Buy Rating on Stryker (SYK)

📈 J.P. Morgan reaffirmed a Buy rating on Stryker (SYK) with a price target of $400.00 in a report released today.

💰 Robbie Marcus, the analyst covering the Healthcare sector at J.P. Morgan, maintains a 51% success rate on his recommended stocks.

✅ Bernstein's Lee Hambright also issued a Buy rating on Stryker in a separate report issued today.

⚠️ Deutsche Bank maintained a Hold rating on Stryker but lowered its price target from $397 to $379.

📉 Other analysts including BTIG, Needham, and Canaccord also lowered their price targets for SYK despite J.P. Morgan's Buy.

💵 Based on Q4 2025 earnings, Stryker reported quarterly revenue of $7.17 billion compared to $6.44 billion the prior year.

📊 Net profit reached $849 million in Q4 2025, up from $546 million during the same period last year.

⚠️ Corporate insider sentiment is negative due to increased selling activity over the past quarter by 53 insiders.

🤵 Ronda Stryker, a Director at SYK, sold 500,000 shares in February 2026 totaling over $181 million.

📰 This article contains third-party content and press releases which have not been reviewed by The Globe and Mail.

Bullish Signals
  • J.P. Morgan reiterated a Buy rating on Stryker (SYK) with a price target of $400.00.
  • Bernstein also maintained a Buy rating on the stock following the latest earnings release.
  • For the quarter ending December 31, Stryker reported quarterly revenue of $7.17 billion, representing significant growth from last year's $6.44 billion.
  • Net profit surged to $849 million for the most recent quarter, compared to $546 million in the same period last year.
  • Robbie Marcus, the analyst covering Stryker, has an impressive track record with a 7.2% average return and a 51.00% success rate on recommended stocks.
Risk Factors
  • Despite a Buy rating from J.P. Morgan, Deutsche Bank maintained a Hold rating on Stryker (NYSE: SYK), indicating mixed analyst sentiment.
  • Corporate insider sentiment is negative with an increase in insider selling over the past quarter.
  • Ronda Stryker, a Director at SYK, sold 500,000 shares for approximately $181.7 million in February 2026, signaling significant insider exit.
  • BTIG lowered its price target to $379 from $397, suggesting a downgrade in valuation expectations.
  • Deutsche Bank reduced its price target to $315 from $402, reflecting a bearish outlook on the stock's upside potential.
  • Needham and Canaccord also cut their price targets by $36 and $35 respectively, indicating growing analyst concern.
Full Analysis
J.P. Morgan analyst Robbie Marcus maintains a Buy rating on Stryker with a price target of $400, citing strong performance in the healthcare sector. While other analysts like Bernstein also issued a Buy rating recently, Deutsche Bank kept its Hold rating, and several other firms including BTIG, Needham, Canaccord, and Deutsche Bank lowered their price targets around that time. Based on Stryker's Q4 earnings for the year ending December 31, the company reported quarterly revenue of $7.17 billion compared to $6.44 billion last year, with net profit rising from $546 million to $849 million. However, insider sentiment is negative as corporate insiders have been selling shares; notably, Director Ronda Stryker sold 500,000 shares in February 2026 for over $181 million, contributing to a decline in insider confidence despite positive earnings.